Renal Nerves Stimulation Study (RNS)

May 4, 2020 updated by: Diagram B.V.

Feasibility of Electrical Mapping and Stimulation of Renal Arteries in Patients Undergoing Renal Denervation

Study design: Investigator initiated, single centre, feasibility study

Main objectives are twofold:

  1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities.
  2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures.

Study population: 40 patients (18 - 80 yr old)

Study Overview

Detailed Description

Background: Approximately 10-15% of adults with hypertension are considered to be treatment resistant because their hypertension is uncontrolled despite taking three or more drugs that includes a diuretic. Renal denervation (RDN) is a novel treatment option for therapy resistant hypertension and its rationale originates in denervating the renal sympathetic efferent and afferent coupling with the central autonomic nervous system. By denervating the renal arteries, general sympathetic tone is reduced. Currently, RDN is performed by placing in a spiral pattern 5-6 ablation lesions in each renal artery. 15-30% of the patients do not have any benefit from this procedure. The reason for this is unknown. Experimental data show that renal nerve stimulation (RNS) may serve as a functional endpoint to assess completeness of the RDN procedure. A RNS-guided RDN may prove to be superior to standard RDN (RNS-checked) in blood pressure control.

Main objectives are twofold:

  1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities.
  2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures.

Secondary objective:

The secondary objective is to compare both techniques (RNS-checked vs. RNS-guided) in terms of efficacy and safety.

Hypotheses:

  • We hypothesize that identification and localization of the sympathetic nerve bundles using 3D navigation systems and selective pacing manoeuvres will allow a functional approach to denervate the kidneys and improve the success rate of this procedure in patients with hypertension.
  • We hypothesize that the RNS-guided RDN procedure will show better blood pressure data during follow up, since the completeness has been assessed in contrast to the RNS-checked RDN procedure.

Study design: Investigator initiated, single centre, prospective, feasibility study

Study population: 40 patients (18 - 80 yr old)

  • 20 patients treated with RNS-checked RDN
  • 20 patients treated with RNS-guided RDN

Intervention:

Two different techniques will be used in this trial:

  1. RNS-checked RDN
  2. RNS-guided RDN

Main study endpoints:

Main study parameter will be the arterial blood pressure response to RNS prior to RDN and absence of blood pressure rise in response to pacing in the renal artery after RDN.

Secondary study endpoints:

Blood pressure at 3, 6, 12 months after the intervention, and change in blood pressure compared to measurement before the intervention.

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Overijssel
      • Zwolle, Overijssel, Netherlands, 8025AB
        • A. Elvan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The patient is willing and able to comply with the protocol and has provided written informed consent.
  • Age 18-80 years
  • The patient has hypertension and is accepted for renal denervation or combined pulmonary bein isolation and renal denervation
  • Glomerular filtration rate >45 mL/min
  • No history of renal artery stenosis

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Contraindication to chronic anticoagulation therapy or heparin.
  • Chronic oxygen use
  • Primary pulmonary hypertension
  • Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age.
  • Known secondary cause of hypertension
  • Mental or physical inability to participate in the study.
  • Renal artery stenosis >50% of the arterial lumen, or renal artery lumen ≤3 mm.
  • Dual or triple ipsilateral renal artery ostia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: RNS-checked RDN
20 patients with hypertension will be enrolled undergoing RNS-checked RDN
Other Names:
  • RNS-checked RDN
Experimental: RNS-guided RDN
20 patients with hypertension will be enrolled undergoing RNS-guided RDN
Other Names:
  • RNS-guided RDN

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
arterial blood pressure response
Time Frame: during procedure
Main study parameter will be the arterial blood pressure response to RNS prior to renal denervation and absence of blood pressure rise in response to pacing in the renal artery after RDN.
during procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood pressure at 3 months
Time Frame: 3 months after the intervention
Blood pressure at 3 months after the intervention
3 months after the intervention
blood pressure at 6 months
Time Frame: 6 months after the intervention
Blood pressure at 6 months after the intervention
6 months after the intervention
blood pressure at 12 months
Time Frame: 12 months after the intervention
Blood pressure at 12 months after the intervention
12 months after the intervention
change in blood pressure compared to measurement before the intervention
Time Frame: intervention - up to 12 months after the intervention
change in blood pressure compared to measurement before the intervention
intervention - up to 12 months after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2014

Primary Completion (Actual)

July 4, 2019

Study Completion (Actual)

July 4, 2019

Study Registration Dates

First Submitted

July 7, 2015

First Submitted That Met QC Criteria

July 13, 2015

First Posted (Estimate)

July 14, 2015

Study Record Updates

Last Update Posted (Actual)

May 6, 2020

Last Update Submitted That Met QC Criteria

May 4, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9209 (OTHER: CTEP)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Electrical mapping, nerve stimulation checked renal denervation procedure

3
Subscribe